Ident. | Authors (with country if any) | Title |
---|
000034 (2013) |
Erwan Bezard [France, République populaire de Chine] ; Elisabetta Tronci [Italie, Suède] ; Elsa Y. Pioli [Royaume-Uni] ; Qin Li [République populaire de Chine, Royaume-Uni] ; Gregory Porras [Royaume-Uni] ; Anders Björklund [Suède] ; Manolo Carta [Italie, Suède] | Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia |
000069 (2013) |
Erwan Bézard [France] ; C. Warren Olanow [États-Unis] ; José A. Obeso [Espagne] | Levodopa–induced dyskinesias in the absence of nigrostriatal degeneration |
000070 (2013) |
Jay S. Schneider [États-Unis] ; Elsa Y. Pioli [République populaire de Chine, Royaume-Uni] ; Yang Jianzhong [République populaire de Chine, Royaume-Uni] ; Qin Li [République populaire de Chine, Royaume-Uni] ; Erwan Bezard [République populaire de Chine, Royaume-Uni, France] | Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model |
000071 (2013) |
Michel Engeln [France] ; Stefania Fasano [Italie] ; Serge H. Ahmed [France] ; Martine Cador [France] ; Veerle Baekelandt [Belgique] ; Erwan Bezard [France] ; Pierre-Olivier Fernagut [France] | Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss |
000072 (2013) |
Alexandre Krainik [France] ; Audrey Maillet [France] ; Vanessa Fleury [France] ; Mehmet Sahin [France] ; Irène Troprès [France] ; Laurent Lamalle [France] ; Stephane Thobois [France] ; Valerie Fraix [France, Suisse] ; Marjorie Villien [France] ; Jan Warnking [France] ; Pierre Pollak [Suisse] ; Serge Pinto [France] ; Paul Krack [France] | Levodopa does not change cerebral vasoreactivity in Parkinson's disease |
000087 (2013) |
C. Warren Olanow [États-Unis, Italie] ; Karl Kieburtz [États-Unis] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Anthony H. Schapira [Royaume-Uni] ; Murat Emre [Turquie] ; Helena Nissinen [Finlande] ; Mika Leinonen [Suède] ; Fabrizio Stocchi [Italie] | Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease |
000123 (2013) |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Alain Destée [France] ; Nobutaka Hattori [Japon] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Werner Poewe [Autriche] ; Mark Stacy [États-Unis] ; Eduardo Tolosa [Espagne] ; Haitao Gao [États-Unis] ; Jennifer Nagel [Suisse] ; Martin Merschhemke [Suisse] ; Ana Graf [Suisse] ; Christopher Kenney [États-Unis] ; Claudia Trenkwalder [Allemagne] | AFQ056 in Parkinson patients with levodopa‐induced dyskinesia: 13‐week, randomized, dose‐finding study |
000508 (2010) |
Jean-Louis Montastruc [France] ; Anne Charlotte Danton [France] ; Genevieve Durrieu [France] ; Isabelle Lacroix [France] ; Pascale Olivier [France] ; Agnés Sommet [France] ; Jean-Michel Senard [France] | Neuropathy as a potential complication of levodopa use in Parkinson's disease: A Pharmacological and Pharmacovigilance point of view |
000515 (2010) |
Daniella Rylander [Suède] ; Martin Parent [Canada] ; Sean S. O'Sullivan [Royaume-Uni] ; Sandra Dovero [France] ; Andrew J. Lees [Royaume-Uni] ; Erwan Bezard [France] ; Laurent Descarries [Canada] ; M. Angela Cenci [Suède] | Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia |
000527 (2010) |
Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [Italie, États-Unis] | Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study |
000626 (2009) |
Julie Charles [France] ; Isabelle Templier [France] ; Dominique Leroux [France] ; Dimitri Salameire [France] ; Caroline Robert [France] ; Sylvie Lantuejoul [France] ; Marie-Therese Leccia [France] | Twenty‐two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson’s disease |
000667 (2009) |
David Devos [France] | Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease |
000764 (2008) |
J. C. Sharma [Royaume-Uni] ; I. N. Ross [Royaume-Uni] ; O. Rascol [France] ; D. Brooks [Royaume-Uni] | Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight |
000785 (2008) |
P. Damier [France] ; F. Viallet [France] ; M. Ziegler [France] ; I. Bourdeix [France] ; K. Rerat [France] | Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort |
000856 (2007) |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa |
000875 (2007) |
Vincent Paillé [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France] | Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias |
000894 (2007) |
A. Gerdelat-Mas [France] ; M. Simonetta-Moreau [France] ; C. Thalamas [France] ; F. Ory-Magne [France] ; T. Slaoui [France] ; O. Rascol [France] ; C. Brefel-Courbon [France] | Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study |
000896 (2007) |
Sonja Krösser [Allemagne] ; Roland Neugebauer [Allemagne] ; Didier Chassard [France] ; Andreas Kovar [Allemagne] | Investigation of the impact of sarizotan on the pharmacokinetics of levodopa |
000963 (2006) |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
000984 (2006) |
Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lled [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne] | Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study |
000A06 (2006) |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardès [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France] | Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease |